Bavarian Nordic A/S
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Paul John Chaplin
- Full Time Employees
- 1,795
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Philip Heymans Alle 3 Hellerup CR Denmark 2900
- IPO Date
- Apr 3, 2013
- Website
- bavarian-nordic.com
- Similar Companies
- Business
- Bavarian Nordic A/S (Ticker: BVNRY) is a biotechnology company focused on developing and manufacturing vaccines for infectious diseases and cancer therapies. The company offers a portfolio of proprietary vaccine platforms, including its MVA-BN non-replicating live viral vector technology used in products such as Jynneos (also known as Imvamune or Imvanex), a vaccine for smallpox and mpox prevention approved in multiple jurisdictions; Vivotif, an oral typhoid vaccine; and Voyxal, a nasal pertussis booster vaccine recently launched in select markets. Additional offerings encompass late-stage candidates like BN226 for glioblastoma and earlier pipeline assets targeting Ebola, RSV, and HPV-related cancers; services include contract development and manufacturing for other biopharma partners utilizing its scalable production capabilities. Bavarian Nordic operates globally across North America, Europe, and emerging markets, serving government stockpiles, healthcare providers, and commercial customers in the infectious disease and oncology segments; founded in 1994, the company is headquartered in Hellerup, Denmark. Recent developments include a major U.S. government contract expansion in 2024 for Jynneos bulk production amid ongoing mpox preparedness, a strategic partnership with Janssen (Johnson & Johnson) advancing the MVA-BN RSV vaccine into Phase 3 trials, and the 2023 commercial launch of Voyxal following EMA approval, alongside a DKK 1.5 billion rights issue to fund pipeline acceleration and manufacturing upgrades.
Company News
Bavarian Nordic A/S (BVNRY) Q2 2026 Earnings Call Transcript
Global warming widens spread of TBE, chikungunya, Bavarian Nordic boss says
Bavarian Nordic A/S (BVNRY) Q1 2026 Earnings Call Transcript
Denmark's Bavarian Nordic raises 2026 forecast
Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic A/S – Notice Convening Annual General Meeting
Bavarian Nordic A/S (BVNRY) Q4 2025 Earnings Call Transcript
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026
Bavarian Nordic – Completion of Share Buy-Back Program
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Short Interest in Bavarian Nordic (OTCMKTS:BVNRY) Drops By 41.9%
Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees
Bavarian Nordic A/S (BVNRY) Q3 2025 Earnings Call Transcript
Bavarian Nordic chair Debruyne steps down after failed takeover
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
Nordic Capital, Permira takeover offer for Bavarian Nordic falls through